drugset / Trial / NCT00818610
Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia
Phase 4
Completed
601 enrolled
Swiss National Fund for Scientific Research
University Hospital, Geneva · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.
Timeline
- Start
- 2009-01
- Primary completion
- 2013-01
- Completion
- 2013-04
Publications
- Chauffard A, Bridevaux PO, Carballo S, Prendki V, Reny JL, Stirnemann J, Garin N. Accuracy of a score predicting the presence of an atypical pathogen in hospitalized patients with moderately severe community-acquired pneumonia. BMC Infect Dis. 2022 May 3;22(1):424. doi: 10.1186/s12879-022-07423-1.
- Garin N, Genne D, Carballo S, Chuard C, Eich G, Hugli O, Lamy O, Nendaz M, Petignat PA, Perneger T, Rutschmann O, Seravalli L, Harbarth S, Perrier A. beta-Lactam monotherapy vs beta-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014 Dec;174(12):1894-901. doi: 10.1001/jamainternmed.2014.4887.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clarithromycin | Small molecule | 0.5 g | Intravenous |
| Background | Amoxicillin | Other / unclassified | 1.2 g | Intravenous |
| Background | Cefuroxime | Small molecule | 1.5 g | Intravenous |